Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TACE + sorafenib
- Development stage
- Phase 3
- Lead developer
- Bayer Pharmaceuticals
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems
- Administration
- Oral, Intra-arterial
01
Overview
TACE + sorafenib is a combination therapy approach for hepatocellular carcinoma (HCC) that combines transarterial chemoembolization (TACE) with the multikinase inhibitor sorafenib. TACE delivers chemotherapeutic medications directly into the hepatic artery supplying the tumor and then embolizes the artery to retain drugs within the tumor, optimizing tumor exposure while reducing systemic toxicity. Sorafenib targets several angiogenesis pathways, including VEGFR2 and PDGFR. The rationale for this combination is that TACE can stimulate VEGF production by residual tumor cells due to hypoxia, potentially leading to increased tumor angiogenesis and formation of collateral circulation. Sorafenib inhibits these angiogenic factors, potentially enhancing TACE efficacy by preventing the development of new blood vessels that could support tumor growth after TACE.
- Brand names
- Nexavar
- Other names
- Sorafenib combined with TACESorafenib plus DEB-TACESorafenib plus TACECombined sorafenib and TACE
02
Targets
PDGFRB (Platelet-derived growth factor receptor beta)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on TACE + sorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TACE + sorafenib.